Replies to post #147005 on Biotech Values

[DewDiligence]

Perhaps Ampyra combined with Bavituximab would be effective in MS.

[biomaven0]

However no one has actually laid out why the FDA won't consider pulling the drug.

Because this was a different endpoint than in their pivotal trial (which was a "responder" based endpoint).

Peter
(no position)

[dewophile]

acor

the stock is green because concern over pts stretching out their pills by breaking them in half is removed

i too have no position btw